Industry Recognition: Acentra Health's inclusion in the NVTC's Tech100 list highlights its exceptional performance in technological innovation and industry leadership, further enhancing its reputation in the healthcare technology sector.
Technology-Driven: The company enhances healthcare analytics and compliance through a unified data platform and the evoBrix® X modular Medicaid Enterprise System, ensuring clients can make faster, more informed decisions that improve health outcomes for millions of beneficiaries.
AI Platform Integration: The Atrezzo AI platform integrates multiple healthcare management functions, increasing efficiency and service quality, thereby helping clients better manage healthcare resources while meeting high standards of care.
Public-Private Collaboration: Acentra Health's involvement in the Safe AI in Medicaid Alliance (SAMA) promotes the responsible use of AI solutions, showcasing the company's leadership in advancing the safe application of healthcare technology.
CG
$57.8+Infinity%1D
Analyst Views on CG
Wall Street analysts forecast CG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CG is 66.70 USD with a low forecast of 51.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast CG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CG is 66.70 USD with a low forecast of 51.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 58.350
Low
51.00
Averages
66.70
High
77.00
Current: 58.350
Low
51.00
Averages
66.70
High
77.00
Barclays
Equal Weight
downgrade
$68 -> $65
2025-12-15
New
Reason
Barclays
Price Target
$68 -> $65
2025-12-15
New
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Carlyle to $65 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the brokers, asset managers and exchanges group as part of its 2026. Market conditions "look constructive" going into 2026, particularly for the alternative asset managers and wealth brokers, the analyst tells investors in a research note. Barclays sees a more mixed outlook for the exchanges and traditional asset managers.
Barclays
Benjamin Budish
Overweight
maintain
$65 -> $68
2025-12-12
New
Reason
Barclays
Benjamin Budish
Price Target
$65 -> $68
2025-12-12
New
maintain
Overweight
Reason
Barclays analyst Benjamin Budish raised the firm's price target on Carlyle to $68 from $65 and keeps an Overweight rating on the shares. The firm adjusted targets in the brokers, asset managers and exchanges group as part of its 2026. Market conditions "look constructive" going into 2026, particularly for the alternative asset managers and wealth brokers, the analyst tells investors in a research note. Barclays sees a more mixed outlook for the exchanges and traditional asset managers.
UBS
Michael Brown
initiated
$74
2025-12-11
New
Reason
UBS
Michael Brown
Price Target
$74
2025-12-11
New
initiated
Reason
UBS analyst Michael Brown assumed coverage of Carlyle with a Buy rating and $74 price target, noting strong sector fundamentals across 20 U.S. asset managers and brokers despite more mixed views on valuations and consensus expectations.The outlook favors undervalued growth, disciplined capital allocation, and firms positioned for margin expansion, while secular tailwinds support wealth brokers and independent investment banks whose robust earnings growth appears partly priced in, the analyst tells investors in a research note.
BofA
Underperform
maintain
$51 -> $53
2025-12-10
Reason
BofA
Price Target
$51 -> $53
2025-12-10
maintain
Underperform
Reason
BofA raised the firm's price target on Carlyle to $53 from $51 and keeps an Underperform rating on the shares. Looking ahead to 2026, the firm now favors the alternative asset managers to online brokers due to what it sees as a better valuation and positioning setup combined with a stronger macro backdrop, the analyst tells investors in a note on the brokers, asset managers and exchanges group.
About CG
The Carlyle Group Inc. is a global investment company. The Company's segments include Global Private Equity, Global Credit and Carlyle AlpInvest. The Global Private Equity segment advises the Company's buyout, growth, real estate, infrastructure, and natural resources funds. The segment also includes the NGP Carry Funds advised by NGP Energy Capital Management (NGP). The Global Credit segment advises funds and vehicles that pursue investment strategies including insurance solutions, liquid credit, opportunistic credit, direct lending, asset-backed finance, aviation finance, infrastructure credit, cross-platform credit products, and global capital markets. The Carlyle AlpInvest segment advises global private equity programs that pursue secondary purchases and financing of existing portfolios, managed co-investment programs, and primary fund investments. The Carlyle AlpInvest segment helps investors meet their objectives through tailored portfolio construction and investment selection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
